Myriad Genetics Forms 5-Year Alliance With MD Anderson to Evaluate Molecular Residual Disease Assay

MT Newswires Live01-07 23:40

Myriad Genetics (MYGN) and the University of Texas MD Anderson Cancer Center said Tuesday that they formed a five-year strategic alliance to accelerate the clinical evaluation and development of Myriad's molecular residual disease, or MRD, assay.

Under the terms of the deal, the parties will collaborate to design studies that will assess the test's utility in breast, gastrointestinal, genitourinary, and gynecological cancers, according to the statement.

Myriad said it will provide funding, MRD testing, and scientific research support, while MD Anderson will head the patient enrollment, sample collection, clinical data analysis and manuscript writing for the studies.

Myriad Genetics shares were up more than 4% in recent trading.

Price: 14.43, Change: +0.65, Percent Change: +4.72

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment